Pan‐Variant SARS‐CoV‐2 Vaccines Induce Protective Immunity by Targeting Conserved Epitopes
Authors:
Open Access
- 27 February 2025
- journal article
- Published by Wiley in Advanced Science
- Vol. 12 (16) , e2409919
Abstract
The development of a globally effective COVID‐19 vaccine faces significant challenges, particularly in redirecting the B‐cell response from immunodominant yet variable regions of viral proteins toward their conserved domains. To address this, an integrated strategy is implemented that combines classical B‐cell epitope prediction with protein‐antibody cluster docking and antibody titer analysis from 30 vaccinated and convalescent individuals. This approach yields stable immunodominant and immunoprevalent B‐cell epitopes capable of eliciting robust antibody responses in BALB/c mice and effectively neutralizing pseudoviruses expressing the Spike protein of SARS‐CoV‐2 variants of concern, including Alpha, Beta, Gamma, Delta, and Omicron. To achieve a broader T‐cell‐based immune response, promiscuous T‐cell epitopes are identified by integrating classical T‐cell epitope predictions, differential scanning fluorimetry, and peptide‐MHC structural analysis. Unique peptides with conserved MHC‐anchoring residues are identified, enabling binding to a spectrum of MHC‐I and MHC‐II haplotypes. These peptides elicit strong interferon gamma responses in human peripheral blood mononuclear cells and demonstrate cross‐species efficacy by activating both CD4+ and CD8+ T‐cells in BALB/c mice. Collectively, these findings highlight the significance of innovative vaccine strategies targeting immunodominant/immunoprevalent B‐cell and promiscuous T‐cell epitopes to drive broad and robust humoral and cellular immune responses against a wide range of SARS‐CoV‐2 variants.Keywords
Funding Information
- Korea Health Industry Development Institute (RS‐2024‐00407544,HV22C0164,andRS‐2024‐00407544)
This publication has 77 references indexed in Scilit:
- The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infectionCell, 2023
- Development of variant‐proof severe acute respiratory syndrome coronavirus 2, pan‐sarbecovirus, and pan‐β‐coronavirus vaccinesJournal of Medical Virology, 2022
- Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunityCell, 2022
- Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cellsCell Reports, 2021
- The immunodominant and neutralization linear epitopes for SARS-CoV-2Cell Reports, 2021
- Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution SerologyCell, 2020
- SARS‐CoV‐2 S1 is superior to the RBD as a COVID‐19 subunit vaccine antigenJournal of Medical Virology, 2020
- Major Histocompatibility Complex: Interaction with Peptides2011
- Role of strong anchor residues in the effective binding of 10-mer and 11-mer peptides to HLA-A*2402 moleculesImmunogenetics, 1996
- Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cellsEuropean Journal of Immunology, 1989